Verification of genes differentially expressed in neuroblastoma tumours: A study of potential tumour suppressor genes

BMC Medical Genomics

Volumn 2, Issue , 2009, Pages

  Thorell, Kaisa ^a,b   Bergman, Annika ^c   Carén, Helena ^a   Nilsson, Staffan ^b   Kogner, Per ^d   Martinsson, Tommy ^a   Abel, Frida ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c Department of Pathology   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ATBF1; TRANSCRIPTION FACTOR CACNA2D3; TRANSCRIPTION FACTOR FUSIP1; TRANSCRIPTION FACTOR GNB1; TRANSCRIPTION FACTOR POU4F2; TRANSCRIPTION FACTOR SLC35E2; TRANSCRIPTION FACTOR TFAP2B; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EPIGENETICS; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE NUMBER; GENETIC DIFFERENCE; HUMAN; INFANT; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; TAQMAN LOW DENSITY ARRAYS; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE;

EID: 70349251320     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-2-53     Document Type: Article

References (48)

1. Neuroblastoma. JM Maris MD Hogarty R Bagatell SL Cohn, Lancet 2007 369 9579 2106 2120 10.1016/S0140-6736(07)60983-0 17586306
2. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. GM Brodeur J Pritchard F Berthold NL Carlsen V Castel RP Castelberry B De Bernardi AE Evans M Favrot F Hedborg, et al. J Clin Oncol 1993 11 8 1466 1477 8336186
3. Prognostic factor in neuroblastoma. AE Evans GJ D'Angio K Propert J Anderson HW Hann, Cancer 1987 59 11 1853 1859 10.1002/1097-0142(19870601)59: 11<1853::AID-CNCR28205911023.0.CO;2-F 3567848
4. Statistical estimation of prognosis for children with neuroblastoma. N Breslow B McCann, Cancer Res 1971 31 12 2098 2103 5120301
5. Neuroblastoma: biological insights into a clinical enigma. GM Brodeur, Nat Rev Cancer 2003 3 3 203 216 10.1038/nrc1014 12612655
6. The biologic basis for neuroblastoma heterogeneity and risk stratification. JM Maris, Curr Opin Pediatr 2005 17 1 7 13 10.1097/01.mop. 0000150631.60571.89 15659956
7. Identification of ALK as a major familial neuroblastoma predisposition gene. YP Mosse M Laudenslager L Longo KA Cole A Wood EF Attiyeh MJ Laquaglia R Sennett JE Lynch P Perri, et al. Nature 2008 455 7215 883 4 10.1038/nature07261 18923503
8. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. H Carén F Abel P Kogner T Martinsson, Biochem J 2008 416 2 153 9 10.1042/BJ20081834 18990089
9. Activating mutations in ALK provide a therapeutic target in neuroblastoma. RE George T Sanda M Hanna S Fröhling W Luther 2nd J Zhang Y Ahn W Zhou WB London P McGrady, et al. Nature 2008 455 7215 975 8 10.1038/nature07397 18923525
10. Oncogenic mutations of ALK kinase in neuroblastoma. Y Chen J Takita YL Choi M Kato M Ohira M Sanada L Wang M Soda A Kikuchi T Igarashi, et al. Nature 2008 455 7215 971 4 10.1038/nature07399 18923524
11. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. I Janoueix-Lerosey D Lequin L Brugières A Ribeiro L de Pontual V Combaret V Raynal A Puisieux G Schleiermacher G Pierron, et al. Nature 2008 455 7215 967 70 10.1038/nature07398 18923523
12. Molecular biology of neuroblastoma. JM Maris KK Matthay, J Clin Oncol 1999 17 7 2264 2279 10561284
13. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. J Khan JS Wei M Ringner LH Saal M Ladanyi F Westermann F Berthold M Schwab CR Antonescu C Peterson, et al. Nat Med 2001 7 6 673 679 10.1038/89044 11385503
14. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. M Fischer A Oberthuer B Brors Y Kahlert M Skowron H Voth P Warnat K Ernestus B Hero F Berthold, Clin Cancer Res 2006 12 17 5118 5128 10.1158/1078-0432.CCR-06-0985 16951229
15. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Q Wang S Diskin E Rappaport E Attiyeh Y Mosse D Shue E Seiser J Jagannathan S Shusterman M Bansal, et al. Cancer Res 2006 66 12 6050 6062 10.1158/0008-5472.CAN-05-4618 16778177
16. Imbalance of the mitochondrial pro- and anti-apoptotic mediators in neuroblastoma tumours with unfavourable biology. F Abel RM Sjoberg S Nilsson P Kogner T Martinsson, Eur J Cancer 2005 41 4 635 646 10.1016/j.ejca.2004.12.021 15737569
17. Expression profiling of favorable and unfavorable neuroblastomas. E Hiyama K Hiyama H Yamaoka T Sueda CP Reynolds T Yokoyama, Pediatr Surg Int 2004 20 1 33 38 10.1007/s00383-003-1077-3 14691637
18. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. L McArdle M McDermott R Purcell D Grehan A O'Meara F Breatnach D Catchpoole AC Culhane I Jeffery WM Gallagher, et al. Carcinogenesis 2004 25 9 1599 1609 10.1093/carcin/bgh173 15090470
19. Non-random inactivation of large common fragile site genes in different cancers. S McAvoy SC Ganapathiraju AL Ducharme-Smith JR Pritchett F Kosari DS Perez Y Zhu CD James DI Smith, Cytogenet Genome Res 2007 118 2-4 260 269 10.1159/000108309 18000379
20. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. M Abe M Ohira A Kaneda Y Yagi S Yamamoto Y Kitano T Takato A Nakagawara T Ushijima, Cancer Res 2005 65 3 828 834 15705880
21. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. B Banelli I Gelvi A Di Vinci P Scaruffi I Casciano G Allemanni S Bonassi GP Tonini M Romani, Oncogene 2005 24 36 5619 5628 10.1038/sj.onc.1208722 16044164
22. The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations could be found in the candidate tumor suppressor gene PHOX2A. A Wilzen S Nilsson RM Sjoberg T Martinsson F Abel, Int J Oncol 2009 34 3 697 705 19212675
23. INRG Task Force. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. T Monclair GM Brodeur PF Ambros HJ Brisse G Cecchetto K Holmes M Kaneko WB London KK Matthay JG Nuchtern, et al. J Clin Oncol 2009 27 2 298 303 10.1200/JCO.2008.16.6876 19047290
24. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. T Martinsson RM Sjoberg F Hedborg P Kogner, Cancer Res 1995 55 23 5681 5686 7585654
25. Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. T Martinsson RM Sjoberg K Hallstensson M Nordling F Hedborg P Kogner, Eur J Cancer 1997 33 12 1997 2001 10.1016/S0959-8049(97)00278- 5 9516841
26. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. H Caren J Erichsen L Olsson C Enerback RM Sjoberg J Abrahamsson P Kogner T Martinsson, BMC Genomics 2008 9 353 10.1186/1471-2164-9-353 18664255
27. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. J Vandesompele K De Preter F Pattyn B Poppe N Van Roy A De Paepe F Speleman, Genome Biol 2002 3 7 ESEARCH0034 10.1186/gb-2002-3-7-research0034 12184808
28. The Wilms' tumor suppressor Wt1 encodes a transcriptional activator of the class IV POU-domain factor Pou4f2 (Brn-3b). KD Wagner N Wagner G Schley H Theres H Scholz, Gene 2003 305 2 217 223 10.1016/S0378-1119(02)01231-3 12609742
29. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. D Takai PA Jones, Proc Natl Acad Sci USA 2002 99 6 3740 3745 10.1073/pnas. 052410099 11891299
30. BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes. GE Tusnady I Simon A Varadi T Aranyi, Nucleic Acids Res 2005 33 1 9 10.1093/nar/gni012 15653630
31. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. K De Preter J Vandesompele P Heimann N Yigit S Beckman A Schramm A Eggert RL Stallings Y Benoit M Renard, et al. Genome Biol 2006 7 9 84 10.1186/gb-2006-7-9-r84 16989664
32. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. M Ohira S Oba Y Nakamura E Isogai S Kaneko A Nakagawa T Hirata H Kubo T Goto S Yamada, et al. Cancer Cell 2005 7 4 337 350 10.1016/j.ccr.2005.03.019 15837623
33. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. A Oberthuer P Warnat Y Kahlert F Westermann R Spitz B Brors B Hero R Eils M Schwab F Berthold, et al. Cancer Lett 2007 250 2 250 267 10.1016/j.canlet.2006.10.016 17126996
34. Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory. D Albino P Scaruffi S Moretti S Coco M Truini C Di Cristofano A Cavazzana S Stigliani S Bonassi GP Tonini, Cancer 2008 113 6 1412 1422 10.1002/cncr.23720 18671248
35. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. P Warnat A Oberthuer M Fischer F Westermann R Eils B Brors, BMC Cancer 2007 7 89 10.1186/1471-2407-7-89 17531100
36. Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. A Eggert MA Grotzer TJ Zuzak N Ikegaki H Zhao GM Brodeur, Eur J Cancer 2002 38 1 92 98 10.1016/S0959-8049(01) 00347-1 11750845
37. Requirement for Brn-3b in early differentiation of postmitotic retinal ganglion cell precursors. M Xiang, Dev Biol 1998 197 2 155 169 10.1006/dbio.1998.8868 9630743
38. The Brn-3b transcription factor regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo. S Irshad RB Pedley J Anderson DS Latchman V Budhram-Mahadeo, J Biol Chem 2004 279 20 21617 21627 10.1074/jbc.M312506200 14970234
39. Post-transcriptional regulation of the Brn-3b transcription factor in differentiating neuroblastoma cells. M Calissano JK Diss DS Latchman, FEBS Lett 2007 581 13 2490 2496 10.1016/j.febslet.2007.04.066 17490655
40. Coupling the transcriptional regulatory action of Brn-3b to the cell cycle clock. T Zhu S Sukumar, Cancer Biol Ther 2004 3 3 324 325 15020847
41. Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells. VS Budhram-Mahadeo S Irshad S Bowen SA Lee L Samady GP Tonini DS Latchman, Oncogene 2008 27 1 145 154 10.1038/sj.onc.1210621 17637757
42. The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells. V Budhram-Mahadeo D Ndisang T Ward BL Weber DS Latchman, Oncogene 1999 18 48 6684 6691 10.1038/sj.onc.1203072 10597274
43. Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression. VS Budhram-Mahadeo S Bowen S Lee C Perez-Sanchez E Ensor PJ Morris DS Latchman, Nucleic Acids Res 2006 34 22 6640 6652 10.1093/nar/gkl878 17145718
44. Localization of Caspr2 in myelinated nerves depends on axon-glia interactions and the generation of barriers along the axon. S Poliak L Gollan D Salomon EO Berglund R Ohara B Ranscht E Peles, J Neurosci 2001 21 19 7568 7575 11567047
45. Common fragile sites, extremely large genes, neural development and cancer. DI Smith Y Zhu S McAvoy R Kuhn, Cancer Lett 2006 232 1 48 57 10.1016/j.canlet.2005.06.049 16221525
46. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. YP Mosse SJ Diskin N Wasserman K Rinaldi EF Attiyeh K Cole J Jagannathan K Bhambhani C Winter JM Maris, Genes Chromosomes Cancer 2007 46 10 936 949 10.1002/gcc.20477 17647283
47. Methylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer. A Wanajo A Sasaki H Nagasaki S Shimada T Otsubo S Owaki Y Shimizu Y Eishi K Kojima Y Nakajima, et al. Gastroenterology 2008 135 2 580 590 10.1053/j.gastro.2008.05.041 18588891
48. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. M Ebauer M Wachtel FK Niggli BW Schafer, Oncogene 2007 26 51 7267 7281 10.1038/sj.onc.1210525 17525748